TY - JOUR
T1 - Non-coding Natural Antisense Transcripts
T2 - Analysis and Application
AU - Krappinger, Julian C.
AU - Bonstingl, Lilli
AU - Pansy, Katrin
AU - Sallinger, Katja
AU - Wreglesworth, Nick I.
AU - Grinninger, Lukas
AU - Deutsch, Alexander
AU - El-Heliebi, Amin
AU - Kroneis, Thomas
AU - Mcfarlane, Ramsay J.
AU - Sensen, Christoph W.
AU - Feichtinger, Julia
N1 - Funding Information:
J.F. and J.C.K. were supported by the Austrian Science Fund (FWF): T923-B26. J.F. and J.C.K. were further supported by the Christian Doppler Research Association. The financial support by the Austrian Federal Ministry for Digital and Economic Affairs and the National Foundation for Research, Technology and Development is gratefully acknowledged. N.I.W. and R.J.M. were supported by a project grant from Cancer Research Wales (award C004135). K.P. was supported by a grant of the DOC Fellowship Programme of the Austrian Academy of Sciences (award 25690), by a research grant of the Austrian Society for Hematology & Medical Oncology (OeGHO) and by the PhD Program in Molecular Medicine (MOLMED) of the Medical University of Graz. J.F. and A.D. were supported by project grants from the MEFOgraz. A.E. T.K. L.B. and K.S. were supported by the Center for Biomarker Research in Medicine (CBmed), which is funded within COMET ? Competence Centers for Excellent Technologies by the Federal Ministry of Transport, Innovation and Technology (BMVIT), the Federal Ministry for Digital and Economic Affairs (BMDW), Land Steiermark (Styrian Business Promotion Agency ? SFG) and Land Wien (Vienna Business Agency ? WAW). The COMET program is executed by the Austrian Research Promotion Agency (FFG). L.B. was supported by the Center for Biomarker Research in Medicine and the Medical University ofGrazvia the PhD Program in Advanced Medical Biomarker Research (AMBRA). K.S. was supported by the Doctoral School in Translational Molecular and Cellular Biosciences at the Medical University of Graz. HCEMM (C.W.S) has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 739539.
Funding Information:
J.F. and J.C.K. were supported by the Austrian Science Fund (FWF): T923-B26. J.F. and J.C.K. were further supported by the Christian Doppler Research Association. The financial support by the Austrian Federal Ministry for Digital and Economic Affairs and the National Foundation for Research, Technology and Development is gratefully acknowledged. N.I.W. and R.J.M. were supported by a project grant from Cancer Research Wales (award C004135). K.P. was supported by a grant of the DOC Fellowship Programme of the Austrian Academy of Sciences (award 25690), by a research grant of the Austrian Society for Hematology & Medical Oncology (OeGHO) and by the PhD Program in Molecular Medicine (MOLMED) of the Medical University of Graz. J.F. and A.D. were supported by project grants from the MEFOgraz . A.E., T.K., L.B. and K.S. were supported by the Center for Biomarker Research in Medicine (CBmed), which is funded within COMET – Competence Centers for Excellent Technologies by the Federal Ministry of Transport, Innovation and Technology (BMVIT) , the Federal Ministry for Digital and Economic Affairs (BMDW) , Land Steiermark (Styrian Business Promotion Agency – SFG) and Land Wien (Vienna Business Agency – WAW). The COMET program is executed by the Austrian Research Promotion Agency (FFG). L.B. was supported by the Center for Biomarker Research in Medicine and the M edical University of Grazvia the PhD Program in Advanced Medical Biomarker Research (AMBRA). K.S. was supported by the Doctoral School in Translational Molecular and Cellular Biosciences at the Medical University of Graz. HCEMM (C.W.S) has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 739539 .
Publisher Copyright:
© 2021 The Authors
PY - 2021/11/10
Y1 - 2021/11/10
N2 - Non-coding natural antisense transcripts (ncNATs) are regulatory RNA molecules that are overlapping with as well as complementary to other transcripts. These transcripts are implicated in a broad variety of biological and pathological processes, including tumorigenesis and oncogenic progression. With this complex field still in its infancy, annotations, expression profiling and functional characterisations of ncNATs are far less comprehensive than those for protein-coding genes, pointing out substantial gaps in the analysis and characterisation of these regulatory transcripts. In this review, we discuss ncNATs from an analysis perspective, in particular regarding the use of high-throughput sequencing strategies, such as RNA-sequencing, and summarize the unique challenges of investigating the antisense transcriptome. Finally, we elaborate on their potential as biomarkers and future targets for treatment, focusing on cancer.
AB - Non-coding natural antisense transcripts (ncNATs) are regulatory RNA molecules that are overlapping with as well as complementary to other transcripts. These transcripts are implicated in a broad variety of biological and pathological processes, including tumorigenesis and oncogenic progression. With this complex field still in its infancy, annotations, expression profiling and functional characterisations of ncNATs are far less comprehensive than those for protein-coding genes, pointing out substantial gaps in the analysis and characterisation of these regulatory transcripts. In this review, we discuss ncNATs from an analysis perspective, in particular regarding the use of high-throughput sequencing strategies, such as RNA-sequencing, and summarize the unique challenges of investigating the antisense transcriptome. Finally, we elaborate on their potential as biomarkers and future targets for treatment, focusing on cancer.
KW - biomarkers
KW - liquid biopsy
KW - long non-coding RNAs
KW - natural antisense transcripts
KW - strand-specific RNA-seq
UR - http://www.scopus.com/inward/record.url?scp=85116059239&partnerID=8YFLogxK
U2 - 10.1016/j.jbiotec.2021.08.005
DO - 10.1016/j.jbiotec.2021.08.005
M3 - Article
C2 - 34371054
AN - SCOPUS:85116059239
SN - 0168-1656
VL - 340
SP - 75
EP - 101
JO - Journal of Biotechnology
JF - Journal of Biotechnology
ER -
